Skip Nav Destination
Advances in Cardiology
Antiplatelet Therapy in ACS and A-Fib
S.Karger AG
Volume
47
Status:
Available
ISBN electronic:
978-3-318-02169-1
ISBN print:
978-3-318-02168-4
Book Series:
Advances in Cardiology
Publication date:
2012
Book Details
Platelets play a critical role in the pathophysiology of acute coronary syndromes (ACS) and thromboembolic complications associated with atrial fibrillation. Anticoagulant and antiplatelet therapies are central to the treatment of ACS and atrial fibrillation. Over the last several decades, a better understanding of the pathogenesis of coronary heart disease and atrial fibrillation has led to refinements in antithrombotic strategies and clinical outcomes. With this in mind, some of the issues outlined in this book are new insights in genetic testing and modification of individualized antiplatelet therapy based on rapid bedside platelet analyzers. Most importantly, the current update of pros and cons of novel antiplatelet agents such as prasugrel and ticagrelor are provided in detail. Conventional antiplatelet strategies with aspirin and clopidogrel are also discussed. Special attention is devoted to experimental antiplatelet agents like PAR-1 thrombin receptor antagonists or aptamers. The ability to focus on different diseases beyond ACS, including heart failure and atrial fibrillation, distinguishes this publication. Each chapter was written by top experts in the field and scientists with the utmost authority and expertise to provide cardiologists, internists, and clinical pharmacologists with the latest updates.
Antiplatelet Therapy in ACS and A-Fib
Edited by: V.L. Serebruany, D. Atar
https://doi.org/10.1159/isbn.978-3-318-02169-1
ISBN (print): 978-3-318-02168-4
ISBN (electronic): 978-3-318-02169-1
Publisher: S.Karger AG
Published: 2012
Download citation file:
Digital Version
Pay-Per-View Access
$167.00
Print Version
Antiplatelet Therapy in ACS and A-Fib
$167.00
Table of Contents
-
1 - 4: IntroductionByVictor L. Serebruany;Victor L. SerebruanyaHeart DrugTM Research Laboratories, Johns Hopkins University, Towson, Md., USA;Search for other works by this author on:Dan AtarDan AtarbDepartment of Cardiology, Oslo University Hospital, Ullevål, Oslo, NorwaySearch for other works by this author on:
-
5 - 19: Impact of Antiplatelet Therapy in Heart DiseaseByGiulia Renda;Giulia RendaInstitute of Cardiology and Center of Excellence on Aging, ‘G. d’Annunzio’ University, Chieti, ItalySearch for other works by this author on:Raffaele de CaterinaRaffaele de CaterinaInstitute of Cardiology and Center of Excellence on Aging, ‘G. d’Annunzio’ University, Chieti, ItalySearch for other works by this author on:
-
20 - 30: Antiplatelet Therapy in Acute Coronary Syndrome and Atrial Fibrillation: AspirinByJean-François TanguayJean-François TanguayDepartment of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, Que., CanadaSearch for other works by this author on:
-
31 - 38: Clopidogrel in Coronary Artery Disease: Update 2012ByKurt HuberKurt Huber3rd Department of Internal Medicine, Cardiology and Emergency Medicine, Wilhelminen Hospital, Vienna, AustriaSearch for other works by this author on:
-
39 - 63: PrasugrelByAntonio Tello-Montoliu;Antonio Tello-MontoliuUniversity of Florida College of Medicine-Jacksonville, Jacksonville, Fla., USASearch for other works by this author on:Salvatore D. Tomasello;Salvatore D. TomaselloUniversity of Florida College of Medicine-Jacksonville, Jacksonville, Fla., USASearch for other works by this author on:Dominick J. AngiolilloDominick J. AngiolilloUniversity of Florida College of Medicine-Jacksonville, Jacksonville, Fla., USASearch for other works by this author on:
-
64 - 77: Antiplatelet Therapy in Acute Coronary Syndromes: TicagrelorBySteen HustedSteen HustedMedical Department, Hospital Unit West, Herning, DenmarkSearch for other works by this author on:
-
78 - 86: Dipyridamole in Antithrombotic TreatmentByWolfgang G. EisertWolfgang G. EisertaDepartment of Biophysics, Leibniz University of Hannover,bDepartment of Neurology, Medical School Hannover (MHH), andcCenter for Thrombosis- and Atherosclerosis Research, Hannover, GermanySearch for other works by this author on:
-
87 - 99: Protease-Activated Receptor-1 Inhibitors: A Novel Class of Antiplatelet Agents for the Treatment of Patients with Acute Coronary SyndromeBySergio Leonardi;Sergio LeonardiaDuke Clinical Research Institute,dDepartment of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, ItalySearch for other works by this author on:Pierluigi Tricoci;Pierluigi TricociaDuke Clinical Research Institute,bDivision of Cardiology, andSearch for other works by this author on:Richard C. BeckerRichard C. BeckeraDuke Clinical Research Institute,cDivision of Hematology, Duke University Medical Center, Durham, N.C., USA;Search for other works by this author on:
-
100 - 113: Genetic ConsiderationsByMatthew J. PriceMatthew J. PriceaCardiac Catheterization Laboratory, Division of Cardiovascular Diseases, Scripps Clinic, andbScripps Translational Science Institute, La Jolla, Calif., USASearch for other works by this author on:
-
114 - 124: Stents and Antiplatelet TherapyByAmir-Ali Fassa;Amir-Ali FassaaCardiology Department, Bichat Hospital, AP-HP, Paris, France;Search for other works by this author on:Philip UrbanPhilip UrbanbCardiovascular Department, La Tour Hospital, Geneva, SwitzerlandSearch for other works by this author on:
-
125 - 140: Bleeding and the Use of Antiplatelet Agents in the Management of Acute Coronary Syndromes and Atrial FibrillationByJohn P. Vavalle;John P. VavalleThe Duke Clinical Research Institute, Durham, N.C., USASearch for other works by this author on:Sunil V. RaoSunil V. RaoThe Duke Clinical Research Institute, Durham, N.C., USASearch for other works by this author on:
-
141 - 154: Antiplatelet Therapy in Stroke PreventionByStavros Apostolakis;Stavros ApostolakisaHaemostasis Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK;Search for other works by this author on:Francisco Marín;Francisco MarínbDepartment of Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, SpainSearch for other works by this author on:Gregory Y.H. LipGregory Y.H. LipaHaemostasis Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK;Search for other works by this author on:
-
155 - 164: Challenges in Atrial FibrillationByRon Pisters;Ron PistersaDepartments of Cardiology andcCardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The NetherlandsSearch for other works by this author on:Hugo ten Cate;Hugo ten CatebInternal Medicine, andcCardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The NetherlandsSearch for other works by this author on:Harry J. CrijnsHarry J. CrijnsaDepartments of Cardiology andcCardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The NetherlandsSearch for other works by this author on:
-
165 - 165: ConclusionByDan Atar;Dan AtaraDepartment of Cardiology, Oslo University Hospital, Ullevål, Oslo, Norway;Search for other works by this author on:Victor L. SerebruanyVictor L. SerebruanybHeart DrugTM Research Laboratories, Johns Hopkins University, Towson, Md., USASearch for other works by this author on:
